tradingkey.logo

Evolus Inc

EOLS
4.500USD
+0.090+2.04%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
291.45MMarktkapitalisierung
VerlustKGV TTM

Evolus Inc

4.500
+0.090+2.04%

mehr Informationen über Evolus Inc Unternehmen

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Evolus Inc Informationen

BörsenkürzelEOLS
Name des UnternehmensEvolus Inc
IPO-datumFeb 08, 2018
CEOMoatazedi (David)
Anzahl der mitarbeiter332
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 08
Addresse520 Newport Center Dr Ste 1200
StadtNEWPORT BEACH
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92660-7022
Telefon19492844555
Websitehttps://www.evolus.com/
BörsenkürzelEOLS
IPO-datumFeb 08, 2018
CEOMoatazedi (David)

Führungskräfte von Evolus Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+23000.00%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
+104603.00%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+30000.00%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-5900.00%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-127905.00%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+23000.00%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
+104603.00%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+30000.00%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-5900.00%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-127905.00%

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Nantahala Capital Management, LLC
8.84%
Tang Capital Management, LLC
8.47%
Lynch (Timothy Patrick)
7.92%
Caligan Partners, LP
6.39%
BlackRock Institutional Trust Company, N.A.
6.15%
Andere
62.24%
Aktionäre
Aktionäre
Anteil
Nantahala Capital Management, LLC
8.84%
Tang Capital Management, LLC
8.47%
Lynch (Timothy Patrick)
7.92%
Caligan Partners, LP
6.39%
BlackRock Institutional Trust Company, N.A.
6.15%
Andere
62.24%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
39.18%
Investment Advisor
21.75%
Investment Advisor/Hedge Fund
15.75%
Individual Investor
10.05%
Private Equity
4.06%
Corporation
3.30%
Research Firm
2.38%
Pension Fund
0.43%
Bank and Trust
0.25%
Andere
2.85%

Institutionelle Beteiligung

Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
356
58.38M
89.22%
--
2025Q3
366
58.59M
90.20%
-409.50K
2025Q2
368
58.97M
91.09%
+3.93M
2025Q1
354
55.05M
88.70%
-1.35M
2024Q4
343
52.59M
87.55%
+1.63M
2024Q3
334
50.95M
89.20%
-1.08M
2024Q2
328
52.17M
86.99%
+2.08M
2024Q1
314
50.10M
82.52%
-553.42K
2023Q4
296
45.99M
83.45%
+2.48M
2023Q3
294
41.91M
82.26%
+3.40M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Nantahala Capital Management, LLC
5.73M
8.84%
+1.53M
+36.42%
Sep 30, 2025
Tang Capital Management, LLC
5.49M
8.47%
+490.90K
+9.82%
Sep 30, 2025
Lynch (Timothy Patrick)
5.13M
7.92%
+1.04M
+25.38%
Sep 30, 2025
Caligan Partners, LP
4.14M
6.39%
+796.97K
+23.85%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.99M
6.15%
+339.54K
+9.30%
Sep 30, 2025
The Vanguard Group, Inc.
3.42M
5.27%
+110.69K
+3.35%
Sep 30, 2025
Frazier Life Sciences Management, L.P.
2.63M
4.06%
+195.12K
+8.01%
Sep 30, 2025
Medy Tox Inc
2.14M
3.3%
-1.24M
-36.82%
Dec 31, 2024
Millennium Management LLC
1.86M
2.87%
+375.58K
+25.32%
Sep 30, 2025
Stonepine Capital Management, LLC
1.54M
2.37%
+619.89K
+67.64%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
State Street SPDR S&P Pharmaceuticals ETF
0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.93%
iShares U.S. Pharmaceuticals ETF
0.15%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Mehr Anzeigen
State Street SPDR S&P Pharmaceuticals ETF
Anteil0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil0.93%
iShares U.S. Pharmaceuticals ETF
Anteil0.15%
iShares Micro-Cap ETF
Anteil0.07%
ProShares Ultra Nasdaq Biotechnology
Anteil0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.06%
Invesco Nasdaq Biotechnology ETF
Anteil0.04%
ProShares Hedge Replication ETF
Anteil0.02%
iShares Russell 2000 Growth ETF
Anteil0.02%
Schwab U.S. Small-Cap ETF
Anteil0.01%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI